Being born with two X chromosomes brings a host of health benefits, and recognising this could lead to personalised medical ...

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...

Tuberculosis (TB) is one of the world's most common infectious diseases. Although infection with the Mycobacterium ...

Cell movement is an essential biological process, whether it's cancer cells metastasizing to other parts of the body or ...

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent ...

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in ...

C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN): On ... two rare kidney diseases with significant complement pathway involvement and no approved therapies. Transforming ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Oct 15 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and Omeros (OMER.O), opens new tab have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's ...

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, scientists preserved cognition in mice without dulling the cancer-killing ...